Eli Lilly Hid Cymbalta Risks, Jury Told As Bellwether Opens

Law360, Los Angeles (August 4, 2015, 9:56 PM EDT) -- Counsel for a woman alleging Eli Lilly & Co. concealed the withdrawal risks of its antidepressant Cymbalta told a California federal jury during opening statements in the bellwether trial Tuesday that the drugmaker's own study revealed almost half of patients who stopped taking the drug risked withdrawal symptoms.

A woman who sued Eli Lilly claims withdrawal symptoms for Cymbalta range from electric-shock sensations in the body and brain, known as "brain zaps," to dizziness, nausea, vomiting, vertigo, excessive sweating, insomnia, nightmares and diarrhea. (Credit: AP) Plaintiff Claudia Herrera is one of hundreds of plaintiffs who have filed suit in state and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!